Amiodarone - A 'broad spectrum' antiarrhythmic drug

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 10, Issue 1, 2010, Pages 73-81

  Punnam, Sujeeth R ^a   Goyal, Sandeep K ^b   Kotaru, Veera Pavan K ^a   Pachika, Ajay R ^c   Abela, George S ^a   Thakur, Ranjan K ^d  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CROZER CHESTER MEDICAL CENTER   (United States)

^d Michigan State University and Sparrow Health System   (United States)

Author keywords

A trial Fibrillation; Amiodarone; Arrhythmias; Drug Toxicity and Ventricular Arrhythmias

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; FLECAINIDE; IBUTILIDE; MACROLIDE; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINOLONE DERIVATIVE; SIMVASTATIN; WARFARIN;

ANTIARRHYTHMIC ACTIVITY; ATAXIA; BRADYCARDIA; BREAST FEEDING; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROPHYSIOLOGY; EYE DISEASE; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART ARRHYTHMIA; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEMODYNAMICS; HUMAN; HYPOTENSION; LIVER TOXICITY; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG DISEASE; MAINTENANCE DRUG DOSE; NEUROTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PREGNANCY; PRIMARY PREVENTION; RECOMMENDED DRUG DOSE; REVIEW; SECONDARY PREVENTION; SINUS RHYTHM; SKIN DISEASE; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; TORSADE DES POINTES; TREMOR;

EID: 77950802451     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152910790780032     Document Type: Review

References (103)

1. Singh, B.N. Amiodarone: historical development and pharmacologic profile. Am. Heart J., 1983, 106, 788-796.
2. Canada, A.T.; Lawrence, L.J.; Haffajee, C.I.; Johnson, B.; Asdourian, GK. Amiodarone for tachyarrhythmias: pharmacology, kinetics, and efficacy. Drug Intell. Clin. Pharm., 1983, 17, 100-104.
3. Work of cardiology community results in approval of amiodarone. FDA Drug Bull., 1986, 16, 4-5.
4. Top 200 generic drugs by retail dollars in 2006. Available at: http://www.drugtopics.com/drugtopics/data/articlestandard/drugtop ics/072007/405102/article.pdf. 2006. [Accessed March 23, 2009].
5. Wellens, H.J.; Brugada, P.; Abdollah, H.; Dassen, W.R. A comparison of the electrophysiologic effects of intravenous and oral amiodarone in the same patient. Circulation, 1984, 69(1), 120-124.
6. Singh, B.; H.J.J.W, BE. H. Electropharmacological Control of Cardiac Arrhythmias. New Tork, NY: Futura Publishing Co 1994.
7. Singh, B.N.; Nademanee, K. Amiodarone and thyroid function: clinical implications during antiarrhythmic therapy. Am. Heart J., 1983, 106(4 Pt 2), 857-869.
8. Singh, S.N.; Fletcher, R.D.; Fisher, S.G.; Singh, B.N.; Lewis, H.D.; Deedwania, P.C.; Massie, B.M.; Colling, C.; Lazzeri, D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N. Engl. J. Med., 1995, 333(2), 77-82.
9. Amiodarone HCI (Pacerone) [package insert]. Minneapolis, MN: Upsher-Smith 2006.
10. Ellenbogen, K.A.; O'Callahan, W.G.; Colavita, Smith, M.S.; German, L.D. Cardiac function in patients on chronic amiodarone therapy. Am. Heart J., 1985, 110, 376-381.
11. Sheldon, R.S.; Mitchell, L.B.; Duff, H.J.; Wyse, D.G.; Manyari, D.E. Right and left ventricular function during chronic amiodarone therapy. Am. J. Cardiol., 1988, 62, 736-740.
12. Remme, W.J.; Van Hoogenhuyze, D.C.; Krauss, X.H.; Hofman, A.; Kruyssen, D.A.; Storm, C.J. Acute hemodynamic and antiischemic effects of intravenous amiodarone. Am. J. Cardiol., 1985, 55: 639-644.
13. Micromedex Healthcare Series. https://www-thomsonhc-com. 2009. Accessed March 23, 2009.
14. Scheinman, M.M.; Levine, J.H.; Cannom, D.S.; Friehling, T.; Kopelman, H.A.; Chilson, D.A.; Platia, E.V.; Wilber, D.J.; Kowey P.R. Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. Circulation, 1995, 92(11), 3264-3272.
15. Goldschlager, N.; Epstein, A.E.; Naccarelli, G.V.; Olshansky, B.; Singh, B.; Collard, H.R.; Murphy, E. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology (HRS). A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm, 2007, 4(9), 1250-1259.
16. Latini, R.; Tognoni, G.; Kates, R.E. Clinical pharmacokinetics of amiodarone. Clin. Pharmacokinet., 1984; 9(2), 136-156.
17. Holt, D.W.; Tucker, G.T.; Jackson, P.R.; Storey, G.C. Amiodarone pharmacokinetics. Am Heart J., 1983, 106(4 Pt 2), 840-847.
18. Heger, J.J.; Prystowsky, E.N.; Zipes, D.P. Relationships between amiodarone dosage, drug concentrations, and adverse side effects. Am. Heart J., 1983, 106(4 Pt 2), 931-935.
19. Lalloz, M.R.; Byfield, P.G.; Greenwood, R.M.; Himsworth, R.L. Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. J. Pharm. Pharmacol., 1984, 36(6), 366-372.
20. Chow, M. Intravenous amiodarone: pharmacology, pharmacokinetics and clinical use. Ann. Pharmacother., 1996, 30, 637-643.
21. Al-Khatib, S.M.; LaPointe; N.M.; Curtis, L.H.; Kramer; J.M.; Swann, J.; Honig, P.; Califf, R.M. Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. Am J Cardiol. Jan 1 2003;91(1):91-94.
22. Zipes, D.; PBRO, L.E. B. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia, PA.: WB Saunders; 2005.
23. Goldschlager, N.; Epstein, A.E.; Naccarelli, G.; Olshansky, B.; Singh, B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch. Intern. Med., 2000, 160(12), 1741-1748.
24. Singh, B.N. Acute management of ventricular arrhythmias: role of antiarrhythmic agents. Pharmacotherapy. Mar-Apr 1997;17(2 Pt 2):56S-64S; discussion 89S-91S.
25. Fuster, V.; Ryden, L.E.; Cannom, D.S.; Crijns, H.J.; Curtis, A.B.; Ellenbogen, K.A.; Halperin, J.L.; Le Heuzey, J.Y.; Kay, G.N.; Lowe, J.E.; Olsson, S.B.; Prystowsky, E.N.; Tamargo, J.L.; Wann, S.; Smith, S.C.; Jr, Jacobs; A.K.; Adams, C.D.; Anderson, J.L.; Antman, E.M.; Halperin, J.L.; Hunt, S.A.; Nishimura, R.; Ornato, J.P.; Page, R.L.; Riegel, B.; Priori, S.G.; Blanc, J.J.; Budaj, A.; Camm, A.J.; Dean, V.; Deckers, J.W.; Despres, C.; Dickstein, K.; Lekakis, J.; McGregor, K.; Metra, M.; Morais, J.; Osterspey, A.; Tamargo, J.L.; Zamorano, J.L. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 2006,114(7), e257-354.
26. Vardas, P.E.; Kochiadakis, G.E.; Igoumenidis, N.E.; Tsatsakis, A.M.; Simantirakis, E.N.; Chlouverakis, G.I. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest, 2000, 117, 1538-1545.
27. Singh, B.N.; Singh, S.N.; Reda, D.J.; Tang, X.C.; Lopez, B.; Harris, C.L.; Fletcher, R.D.; Sharma, S.C.; Atwood, J.E.; Jacobson, A.K.; Lewis, H.D.; Jr, Raisch, D.W.; Ezekowitz, M.D. Amiodarone versus sotalol for atrial fibrillation. N. Engl. J. Med., 2005; 352(18),1861-1872.
28. Letelier, L.M.; Udol, K.; Ena, J.; Weaver, B.; Guyatt, G.H. Effectiveness of amiodarone for conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med., 2003, 163(7), 777-785.
29. Chevalier, P.; Durand-Dubief, A.; Burri, H.; Cucherat, M.; Kirkorian, G.; Touboul, P. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J. Am. Coll. Cardiol., 2003, 41(2): 255-262.
30. Hilleman, D.E.; Spinler, S.A. Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. Pharmacotherapy, 2002, 22(1): 66-74.
31. Wyse, D.G.; Waldo, A.L.; DiMarco, J.P.; Domanski, M.J.; Rosenberg, Y.; Schron, E.B.; Kellen, J.C.; Greene, H.L.; Mickel, M.C.; Dalquist, J.E.; Corley, S.D. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med., 2002, 347(23), 1825-1833.
32. Snow, V.; Weiss, K.B.; LeFevre, M.; McNamara, R.; Bass, E.; Green, L.A.; Michl, K.; Owens, D.K.; Susman, J.; Allen, D.I.; Mottur-Pilson, C. AAFP Panel on Atrial Fibrillation; ACP Panel on Atrial Fibrillation. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann. Intern. Med., 2003, 139(12), 1009-1017.
33. Lundstrom, T.; Ryden, L. Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med. Scand., 1988, 223(1), 53-59.
34. Roy, D.; Talajic, M.; Dorian, P.; Connolly, S.; Eisenberg, M.J.; Green, M.; Kus, T.; Lambert, J.; Dubuc, M.; Gagné, P.; Nattel, S.; Thibault, B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N. Engl. J. Med. 2000, 342(13), 913-920.
35. Kochiadakis, G.E.; Igoumenidis, N.E.; Marketou, M.E.; Kaleboubas, M.D.; Simantirakis, E.N.; Vardas, P.E. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart, 2000; 84(3), s251-257.
36. Naccarelli, G.V.; Wolbrette, D.L.; Bhatta, L.; Khan, M.; Hynes, J.; Samii, S.; Luck, J. A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation. J. Interv. Card Electrophysiol., 2003, 9(2), 215-222.
37. Lafuente-Lafuente, C.; Mouly, S.; Longas-Tejero, M.A.; Mahe, I.; Bergmann, J.F. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch. Intern. Med., 2006, 166(7), 719-728.
38. Tamariz, L.J.; Bass, E.B. Pharmacological rate control of atrial fibrillation. Cardiol Clin., 2004, 22(1), 35-45.
39. Donovan, K.; Power, B.; Hockings, B.; Dobb, G.; Lee, K. Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am. J. Cardiol., 1995, 75(10), 693-697.
40. Natale, A.; Newby, K.H.; Pisano, E.; Leonelli, F.; Fanelli, R.; Potenza, D.; Beheiry, S.; Tomassoni, G. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J. Am. Coll. Cardiol., 2000, 35(7), 1898-1904.
41. Da Costa, A.; Thevenin, J.; Roche, F.; Romeyer-Bouchard, C.; Abdellaoui, L.; Messier, M.; Denis, L.; Faure, E.; Gonthier, R.; Kruszynski, G.; Pages, J.M.; Bonijoly, S.; Lamaison, D.; Defaye, P.; Barthélemy, J.C.; Gouttard, T.; Isaaz, K.; Loire-Ardèche- Drôme-Isère-Puy-de-Dôme Trial of Atrial Flutter Investigators. Results from the Loire-Ardeche-Drome- Isere-Puy-de-Dome (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter. Circulation 2006, 114(16), 1676-1681.
42. Kouvaras, G.; Cokkinos, D.V.; Halal, G.; Chronopoulos, G.; Ioannou, N. The effective treatment of multifocal atrial tachycardia with amiodarone. Jpn. Heart J., 1989, 30(3), 301-312.
43. Paul, T.; Bertram, H.; Bokenkamp, R.; Hausdorf, G. Supraventricular tachycardia in infants, children and adolescents: diagnosis, and pharmacological and interventional therapy. Paediatr. Drugs, 2000, 2(3), 171-181.
44. Crystal, E.; Garfinkle, M.S.; Connolly, S.S.; Ginger, T.T.; Sleik, K.; Yusuf, S.S. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane. Database Syst. Rev., 2004(4), CD003611.
45. Mitchell, L.B.; Powell, J.L.; Gillis, A.M.; Kehl, V.; Hallstrom, A.P. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the Antiarrhythmics versus Implantable Defibrillators (AVID) trial. J. Am. Coll. Cardiol., 2003, 42(1), 81-87.
46. Roshanali, F.; Mandegar, M.H.; Yousefnia, M.A.; Alaeddini, F.; Saidi, B. Prevention of atrial fibrillation after coronary artery bypass grafting via atrial electromechanical interval and use of amiodarone prophylaxis. Interact. Cardiovasc. Thorac. Surg., 2009, 8(4), 421-425.
47. Dorian, P.; Cass, D.; Schwartz, B.; Cooper, R.; Gelaznikas, R.; Barr, A. Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation. N. Engl. J. Med., 2002, 346(12), 884-890.
48. Fogel, R.I.; Herre, J.M.; Kopelman, H.A.; Kowey, P.R.; Trohman, R.G.; Fineberg, N.; Prystowsky, E.N. Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias. Am. Heart J., 2000,139(4), 690-695.
49. Raitt, M.H.; Renfroe, E.G.; Epstein, A.E.; McAnulty, J.H.; Mounsey, P.; Steinberg, J.S.; Lancaster, S.E.; Jadonath, R.L.; Hallstrom, A.P. Antiarrhythmics Versus Implantable Defibrillators investigators. "Stable" ventricular tachycardia is not a benign rhythm : insights from the antiarrhythmics versus implantable defibrillators (AVID) registry. Circulation, 2001; 103(2), 244-252.
50. Echt, D.S.; Liebson, P.R.; Mitchell, L.B.; Peters, R.W.; Obias-Manno, D.; Barker, A.H.; Arensberg, D.; Baker, A.; Friedman, L.; Greene, H.L. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 1991; 324(12):781-788.
51. Cairns, J.A.; Connolly, S.J.; Roberts, R.; Gent, M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet, 1997, 349(9053), 675-682.
52. Julian, D.G.; Camm, A.J.; Frangin, G.; Janse, M.J.; Munoz, A.; Schwartz, P.J.; Simon, P. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet, 1997, 349(9053), 667-674.
53. Nuttall, S.L.; Toescu, V.; Kendall, M.J. beta Blockade after myocardial infarction. Beta blockers have key role in reducing morbidity and mortality after infarction. B.M.J., 2000, 320(7234), 581.
54. Moss, A.J.; Hall, W.J.; Cannom, D.S.; Daubert, J.P.; Higgins, S.L.; Klein, H.; Levine, J.H.; Saksena, S.; Waldo, A.L.; Wilber, D.; Brown, M.W.; Heo, M.. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N. Engl. J. Med., 1996, 335(26),1933-1940.
55. Buxton, A.E.; Lee, K.L.; Fisher, J.D.; Josephson, M.E.; Prystowsky, E.N.; Hafley, G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N. Engl. J. Med., 1999, 341(25),1882-1890.
56. Moss, A.J.; Zareba, W.; Hall, W.J.; Klein, H.; Wilber, D.J.; Cannom, D.S.; Daubert, J.P.; Higgins, S.L.; Brown, M..W.; Andrews, M.L.; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med., 2002, 346(12), 877-883.
57. Bardy, G.H.; Lee, K.L.; Mark, D.B.; Poole, J.E.; Packer, D.L.; Boineau, R.; Domanski, M.; Troutman, C.; Anderson, J.; Johnson, G.; McNulty, S.E.; Clapp-Channing, N.; Davidson-Ray, L.D.; Fraulo, E.S.; Fishbein, D.P.; Luceri, R.M.; Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med., 2005, 352(3), 225-237.
58. Connolly, S.J.; Hallstrom, A.P.; Cappato, R.; Schron, E.B.; Kuck, K.H.; Zipes, D.P.; Greene, H.L.; Boczor, S.; Domanski, M.; Follmann, D.; Gent, M.; Roberts, R.S. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study. Eur. Heart J., 2000, 21(24), 2071-2078.
59. Kuck, K.H.; Cappato, R.; Siebels, J.; Ruppel, R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation, 2000, 102(7), 748-754.
60. Listed, N.A. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators. N. Engl. J. Med., 1997, 337(22), 1576-1583.
61. Pinski, S.L.; Sgarbossa, E.B.; Maloney, J.D.; Trohman, R.G. Survival in patients declining implantable cardioverter-defibrillators. Am. J. Cardiol., 1991, 68(8), 800-801.
62. Maron, B.J.; Spirito, P.; Shen, W.K.; Haas, T.S.; Formisano, F.; Link, M.S.; Epstein, A.E.; Almquist, A.K.; Daubert, J.P.; Lawrenz, T.; Boriani, G.; Estes, N.A.; 3rd, Favale, S.; Piccininno, M.; Winters, S.L.; Santini, M.; Betocchi, S.; Arribas, F.; Sherrid, M.V.; Buja, G.; Semsarian, C.; Bruzzi, P. Implantable cardioverter defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA, 2007, 298(4), 405-412.
63. Raeder, E.A.; Podrid, P.J.; Lown, B. Side effects and complications of amiodarone therapy. Am. Heart J., 1985, 109, 975-983.
64. Santaella, R.M.; Fraunfelder, F.W. Ocular adverse effects associated with systemic medications : recognition and management. Drugs, 2007, 67(1):75-93.
65. Mantyjarvi, M.; Tuppurainen, K.; Ikaheimo, K. Ocular side effects of amiodarone. Surv. Ophthalmol., 1998, 42(4), 360-366.
66. Ingram, D.V. Ocular effects in long-term amiodarone therapy. Am. Heart J., 1983, 106(4 Pt 2), 902-905.
67. Vorperian, V.R.; Havighurst, T.C.; Miller, S.; January, C.T. Adverse effects of low dose amiodarone: a meta-analysis. J. Am. Coll. Cardiol., 1997, 30(3), 791-798.
68. Feiner, L.A.; Younge, B.R.; Kazmier, F.J.; Stricker, B.H.; Fraunfelder, F.T. Optic neuropathy and amiodarone therapy. Mayo. Clin. Proc., 1987, 62(8), 702-717.
69. Macaluso, D.C.; Shults, W.T.; Fraunfelder, F.T. Features of amiodarone-induced optic neuropathy. Am. J. Ophthalmol., 1999, 127(5), 610-612.
70. Flach, A.J.; Dolan, B.J. Progression of amiodarone induced cataracts. Doc. Ophthalmol., 1993, 83(4), 323-329.
71. Siddoway, L.A. Amiodarone: guidelines for use and monitoring. Am. Fam. Physician., 2003, 68(11), 2189-2196.
72. Albert, S.G.; Alves, L.E.; Rose, E.P. Thyroid dysfunction during chronic amiodarone therapy. J. Am. Coll. Cardiol., 1987, 9(1),175-183.
73. Harjai, K.J.; Licata, A.A. Effects of amiodarone on thyroid function. Ann. Intern. Med., 1997, 126(1), 63-73.
74. Martino, E.; Safran, M.; Aghini-Lombardi, F.; Rajatanavin, R.; Lenziardi, M.; Fay, M.; Pacchiarotti, A.; Aronin, N.; Macchia, E.; Haffajee, C. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann. Intern. Med., 1984, 101(1): 28-34.
75. Basaria, S.; Cooper, D.S. Amiodarone and the thyroid. Am. J. Med., 2005, 118(7), 706-714.
76. Bartalena, L.; Brogioni, S.; Grasso, L.; Bogazzi, F.; Burelli, A.; Martino, E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J. Clin. Endocrinol. Metab., 1996, 81(8), 2930-2933.
77. Meurisse, M.; Hamoir, E.; D'Silva, M.; Joris, J.; Hennen, G. Amiodarone-induced thyrotoxicosis: is there a place for surgery? World J. Surg., 1993, 17(5), 622-626; discussion 627.
78. Fogoros, R.N.; Anderson, K.P.; Winkle, R.A.; Swerdlow, C.D.; Mason, J.W. Amiodarone: clinical efficacy and toxicity in 96 patients with recurrent, drug-refractory arrhythmias. Circulation, 1983, 68(1), 88-94.
79. McGovern, B.; Garan, H.; Kelly, E.; Ruskin, J.N. Adverse reactions during treatment with amiodarone hydrochloride. Br. Med. J. (Clin Res Ed)., 1983, 287(6386), 175-180.
80. Harris, L.; McKenna, W.J.; Rowland, E.; Krikler, D.M. Side effects and possible contraindications of amiodarone use. Am. Heart J., 1983, 106(4 Pt 2), 916-923.
81. Rotmensch, H.H.; Belhassen, B.; Swanson, B.N.; Shoshani, D.; Spielman, S.R.; Greenspon, A.J.; Greenspan, A.M.; Vlasses, P.H.; Horowitz, L.N. Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. Ann. Intern. Med., 1984,101(4), 462-469.
82. Morse, R.M.; Valenzuela, G.A.; Greenwald, T.P.; Eulie, P.J.; Wesley, R.C.; McCallum, R.W. Amiodarone-induced liver toxicity. Ann. Intern. Med., 1988, 109(10), 838-840.
83. Richer, M.; Robert, S. Fatal hepatotoxicity following oral administration of amiodarone. Ann. Pharmacother., 1995, 29(6), 582-586.
84. Mason, J.W. Amiodarone. N. Engl. J. Med., 1987, 316(8), 455-466.
85. Counihan, P.J.; McKenna, W.J. Low-dose amiodarone for the treatment of arrhythmias in hypertrophic cardiomyopathy. J. Clin. Pharmacol., 1989, 29(5), 436-438.
86. Kerin, N.Z.; Aragon, E.; Faitel, K.; Frumin, H.; Rubenfire, M. Long-term efficacy and toxicity of high- and low-dose amiodarone regimens. J. Clin. Pharmacol., 1989, 29(5), 418-423.
87. Greene, H.L.; Graham, E.L.; Werner, J.A.; Sears, G.K.; Gross, B.W.; Gorham, J.P.; Kudenchuk, .P.J.; Trobaugh, G.B. Toxic and therapeutic effects of amiodarone in the treatment of cardiac arrhythmias. J. Am. Coll. Cardiol., 1983, 2(6), 1114-1128.
88. Naccarelli, G.V.; Rinkenberger, R.L.; Dougherty, A.H.; Giebel, R.A. Amiodarone: pharmacology and antiarrhythmic and adverse effects. Pharmacotherapy, 1985, 5, 298-313.
89. Gill, J.; Heel, R.C.; Fitton, A. Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs, 1992, 43(1), 69-110.
90. Weinberg, B.A.; Miles, W.M.; Klein, L.S.; Bolander, J.E.; Dusman, R.E.; Stanton, M.S.; Heger, J.J.; Langefeld, C.; Zipes, D.P. Five-year follow-up of 589 patients treated with amiodarone. Am. Heart J., 1993, 125(1), 109-120.
91. Olshansky, B.; Sami, M.; Rubin, A.; Kostis, J.; Shorofsky, S.; Slee, A.; Greene, H.L.; NHLBI AFFIRM Investigators. Use of amiodarone for atrial fibrillation in patients with preexisting pulmonary disease in the AFFIRM study. Am. J. Cardiol., 2005, 95(3), 404-405.
92. Ernawati, D.K.; Stafford, L.; Hughes, J.D. Amiodarone-induced pulmonary toxicity. Br. J. Clin. Pharmacol., 2008, 66(1), 82-87.
93. Kennedy, J.I.; Myers, J.L.; Plumb, V.J.; Fulmer, J.D. Amiodarone pulmonary toxicity. Clinical, radiologic, and pathologic correlations. Arch. Intern. Med., 1987, 147(1), 50-55.
94. Adams, P.C.; Gibson, G.J.; Morley, A.R.; Wright, A.J.; Corris, P.A. Reid; D.S. Campbell RW. Amiodarone pulmonary toxicity: clinical and subclinical features. Q J. Med.,1986, 59(229), 449-471.
95. Myers, J.L.; Kennedy, J.I.; Plumb, V.J. Amiodarone lung: pathologic findings in clinically toxic patients. Hum. Pathol., 1987, 18(4), 349-354.
96. Essebag, V.; Hadjis, T.; Platt, R.W.; Pilote, L. Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction. J. Am. Coll. Cardiol., 2003, 41(2), 249-254.
97. Willis, M.S.; Lugo, A.M. Amiodarone-induced neurotoxicity. Am. J. Health Syst. Pharm., 2009, 66(6), 567-569.
98. Libersa, C.C.; Brique, S.A.; Motte, K.B.; Caron, J.F.; Guédon- Moreau, L.M.; Humbert, L.; Vincent, A.; Devos, P.; Lhermitte, M.A. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br. J. Clin. Pharmacol., 2000, 49(4), 373-378.
99. Davy, J.M.; Herold, M.; Hoglund, C.; Timmermans, A.; Alings, A.; Radzik, D.; Van Kempen, L. ERATO Study Investigators. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am. Heart J., 2008, 156(3), 527 e521-529.
100. Singh, B.N.; Connolly, S.J.; Crijns, H.J.; Roy, D.; Kowey, P.R.; Capucci, A.; Radzik, D.; Aliot, E.M. Hohnloser, S.H. EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N. Engl. J. Med., 2007, 357(10), 987-999.
101. Hohnloser, S.H.; Crijns, H.J.; van Eickels, M.; Gaudin, C.; Page, R.L. Torp-Pedersen C, Connolly SJ; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med., 2009, 360(7), 668-678.
102. Kober, L.; Torp-Pedersen, C.; McMurray, J.J.; Gøtzsche, O.; Lévy, S. Crijns, H. Amlie, J.; Carlsen, J. Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N. Engl. J. Med., 2008, 358(25), 2678-2687.
103. LS G, A G. Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11th ed. New Tork, NY: McGraw-Hill; 2005.